FIELD: antibodies.
SUBSTANCE: invention is related to new molecules of bispecific antibodies that bind CD3δε and BCMA, capable of activating immune effector cells, and their use in the diagnosis and/or treatment of various diseases.
EFFECT: invention makes it possible to obtain bispecific antibodies for therapeutic use to support antitumor effects while simultaneously reducing the release of proinflammatory cytokines.
25 cl, 10 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY AND USE THEREOF | 2021 |
|
RU2839153C2 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2779489C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| IMPROVED ANTI-FLT3 ANTIGEN-BINDING PROTEINS | 2019 |
|
RU2830982C2 |
| ANTIBODIES AGAINST GUCY2c AND THEIR USE | 2019 |
|
RU2812113C2 |
| PROTEASE-ACTIVATED T-CELL BINDING BISPECIFIC MOLECULES | 2017 |
|
RU2830288C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| BISPECIFIC ANTIBODY | 2021 |
|
RU2840407C1 |
